SYLVIA AND CHARLES VIERTEL CHARITABLE FOUNDATION MARKS 30 YEARS MILESTONE IN FUNDING RESEARCH New Fellowships to researchers in cancer metastasis, epigenomics and AI in early disease diagnosis & management
With
Associate Professor Paul Ekert, Co-Chair,
Medical Advisory Board, Sylvia and Charles Viertel Charitable Foundation
SEGMENT
Filmed in Sydney, Melbourne & Adelaide | December 2025
One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.
In late October 2025, the Sylvia and Charles Viertel Charitable Foundation, in association with Bellberry, announced the recipients of the 2025 Viertel Senior Medical Research Fellowships. Three Australian mid-career researchers who are advancing solutions for major illnesses including cancer, cardiovascular disease, and neurodegenerative diseases. The 2025 Viertel Senior Medical Research Fellows, who will each receive $1.375 million over five years to support their work, are:
- Dr Joanna Achinger-Kawecka, SAiGENCI for her work in advancing cancer therapy utilising innovative 3D chromatin structure mapping technology.
- Dr Dustin Flanagan, Monash Biomedicine Discovery Institute, Monash University, for addressing the impact of direct cell damage on gastric cancer initiation and progression.
- Associate Professor Zongyuan Ge, Monash AIM for Health Lab, Monash University for developing a personalised healthcare model integrating diverse patient information collected over time via AI. He is the recipient of a Bellberry-Viertel Senior Medical Research Fellowship.
The Viertel Foundation over 30 years has had significant impact in medical research, including
- Awarding 70 fellowships since 1995, each currently providing $1.375 million over five years to support Australia’s top mid-career researchers.
- 162 Clinical Investigator Awards providing $90,000 over one year have been granted, supporting early-career clinicians and stimulating clinical research across Australia.
- Research infrastructure grants totalling $2.45 million have been awarded, recognising the importance of establishing and maintaining the facilities required for world-class research environments.
- The combined total value of the Clinical Investigator Awards, the Fellowships, and infrastructure grants – including the most recent awards has reached $90,001,250. This substantial investment underscores the Foundation’s enduring commitment to advancing medical research and improving health outcomes for Australians.
- Funding has enabled breakthroughs in cancer, infectious diseases, respiratory illnesses, dementia, stem cell research, and more – directly impacting millions of Australians each year.
Source: Adapted from Equity Trustees media release
Photo Credit: Charles Viertel Photo, Queensland Eye Institute
Photo Credit: AAHMS Gala Dinner, Canberra November 2025, Australian Academy of Health and Medical Sciences
-
Jamie Stanistreet talks Medical Technology
Jamie Stanistreet
Retired Managing Director Medtronic Australia and New Zealand
talks Medical Technology in Australia and the Asia-Pacific -
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
